Every year, thousands of Americans need a liver transplant.
But there's a problem. There simply aren't enough donated livers to go around. And even for patients fortunate enough to receive one, the procedure can cost more than $1 million, followed by a lifetime of medical monitoring and medications.
HepaTx wants to offer a different solution.
Instead of replacing a patient's entire liver, this biotech startup is developing a treatment designed to repair the damaged organ using healthy, lab-grown cells. Its goal is to turn one of medicine's most complicated surgeries into a much simpler treatment.
HepaTx has raised more than $2.4 million in venture funding, including investments from Y Combinator, Asymmetry Ventures, and Grey Sky Venture Partners. It's also received $700,000 in grant funding and participated in Stanford's StartX accelerator.
The company's technology originated at Stanford University. Here's how it works:
HepaTx uses specialized techniques to transform cells derived from fat tissue into cells that behave like healthy liver cells. These new cells are designed to replace damaged tissue and help restore the liver's ability to perform essential functions, such as filtering toxins and processing nutrients.
Rather than replacing the entire organ, doctors could potentially administer the cells to help the patient's existing liver recover.
The company is developing this technology as an off-the-shelf treatment, meaning it aims to manufacture doses in advance rather than produce a customized therapy for every patient. That could make the treatment easier to distribute and potentially less expensive than a traditional transplant.
HepaTx's lead product, Hx-001, is initially targeting patients with serious liver damage. Potential applications include metabolic dysfunction-associated steatohepatitis (MASH), alcohol-related hepatitis, autoimmune hepatitis, and acute-on-chronic liver failure.
These conditions represent a significant medical challenge. According to HepaTx, more than 30 million Americans suffer from liver disease, and over one million people develop end-stage liver failure annually.
For patients whose livers can no longer function properly, transplantation may be the only remaining option. But a transplant can cost upwards of $1.25 million, creating a substantial financial burden for patients, insurers, and healthcare systems.
HepaTx believes its cell therapy could offer a more accessible alternative. It has established a collaboration and licensing agreement with the Mayo Clinic to help advance Hx-001 toward its first human trial.
HepaTx is targeting an Investigational New Drug application with the FDA in 2027, followed by an initial clinical trial in 2027 or 2028.
If successful, this study would represent an important step toward demonstrating that its technology can be safely administered to patients.
But HepaTx's ambitions extend beyond a single treatment. The company is developing additional versions of its cell-therapy technology, including Hx-002 and Hx-003, that could eventually address different forms of liver disease.
It's also developing ProteoTrack, a technology intended to help evaluate and optimize its therapies.
The potential market is substantial. The global market for liver-disease treatments generates billions of dollars annually, while liver transplantation itself represents a multibillion-dollar healthcare expense.
HepaTx's business model centers on developing and commercializing its cell therapies, potentially generating revenue through treatment sales and partnerships with larger pharmaceutical companies.
The company remains preclinical, meaning it hasn't yet demonstrated that Hx-001 works in human patients. But its technology, institutional relationships, and investor backing provide a foundation for the next stage of development.